GlassScriptPhysician profile
James M Herrold
NPI 1235166885
$6,258.43
in general payments reported to CMS, 2019-2025
27 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $342 · 2021: $820 · 2022: $1,150 · 2023: $1,096 · 2024: $716 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350 · Consulting Fee: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.02 |
| Consulting Fee | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,207.12 | 2021-2025 | |
| Celgene Corporation | $786.25 | 2020-2025 | Zeposia |
| Biogen, INC. | $712.48 | 2019-2025 | Tysabri, Vumerity |
| Ucb, INC. | $529.77 | 2019-2025 | Briviact, Fintepla |
| E.R. Squibb & Sons, L.L.C. | $498.77 | 2021-2023 | Zeposia |
| Emd Serono, INC. | $457.87 | 2019 | |
| Genentech USA, INC. | $412.46 | 2021-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Lilly USA, LLC | $296.42 | 2019-2025 | Reyvow, Emgality, Kisunla |
| Novartis Pharmaceuticals Corporation | $167.92 | 2019-2022 | |
| Allergan, INC. | $167.75 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $166.81 | 2019 | |
| Tg Therapeutics, INC. | $113.36 | 2023-2025 | |
| Amgen INC. | $111.20 | 2021-2024 | Aimovig |
| Eisai INC. | $103.61 | 2025 | |
| Lundbeck LLC | $82.41 | 2022-2024 | Vyepti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $76.05 | 2019 | |
| Genentech, INC. | $68.10 | 2020-2024 | Ocrevus |
| Sk Life Science, INC. | $53.71 | 2020 | |
| C2n Diagnostics, LLC | $46.24 | 2025 | Precivityad2 |
| Biohaven Pharmaceuticals, INC. | $39.21 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $34.21 | 2023-2024 | Rytary |
| Tanabe Pharma America, INC. | $32.99 | 2023-2024 | |
| Axsome Therapeutics, INC. | $26.65 | 2025 | Symbravo |
| Kyowa Kirin, INC. | $21.13 | 2021 | |
| Abbott Laboratories | $20.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.07 | 2021 | |
| Strongbridge US INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Herrold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.